Background and study aims: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is now performed routinely
in many advanced endoscopy centers and has enhanced the ability to diagnose pancreatic
masses. However, there is uncertainty about which needle size is optimal for EUS-FNA
of pancreatic masses. We aimed to evaluate the performance of the 22-gauge and 25-gauge
needles in obtaining cytologic diagnosis of pancreatic masses.
Methods: All cases that were referred for EUS-FNA for pancreatic masses between February 2001
and June 2007 were reviewed, and patients who underwent EUS-FNA using the 22-gauge
and 25-gauge needle system were identified. In patients who underwent surgery, operative
histopathological findings were compared with the cytopathological findings from EUS-FNA.
Results: A total of 842 patients with pancreatic masses detected on computed tomography (CT)
and/or magnetic resonance imaging (MRI) and confirmed by EUS underwent EUS-FNA with
the 22-gauge needle (n = 540) or the 25-gauge needle (n = 302). Results of EUS-FNA
cytology findings were compared with the gold standard of surgical histopathological
findings or long-term clinical follow-up. The sensitivity, specificity, PPV, and NPV
of FNA were respectively 84 %, 100 %, 100 %, and 49 % for the 22-gauge needle compared
with 92 %, 97 %, 98 %, and 89 %, respectively for the 25-gauge needle. No complications
were noted in the 25-gauge needle group, compared with pancreatitis in 2 % of the
22-gauge needle group.
Conclusions: This retrospective comparative study shows that EUS-FNA with a 25-gauge needle system
is a safe and reliable method for tissue sampling in pancreatic masses. The system
is more sensitive and has a higher NPV than the standard 22-gauge needle. Our study
suggests that perhaps the smaller caliber FNA needle causes less trauma during EUS-FNA
and hence less complications. Further studies including randomized trials are needed.
References
http://seer.cancer.gov/statfacts/html/pancreas.html; Stand: 2008
tyusuf@yahoo.com
